19 citations
,
March 2010 in “Steroids” Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
December 2024 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows promise by targeting androgen receptors.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
36 citations
,
July 2020 in “Frontiers in Medicine” Spironolactone might help protect against severe lung problems in COVID-19 patients.
30 citations
,
September 2016 in “BMJ” Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
April 2026 in “Quality in Sport” Anabolic-androgenic steroids increase the risk of heart problems.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
September 2025 in “Deleted Journal” Blocking androgen receptors boosts macrophages' ability to clear certain bacteria.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.